Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels,…
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels,…
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
This is the second deal announced between Rani and Celltrion, building upon a previously announced…
This is the second deal announced between Rani and Celltrion, building upon a previously announced…
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…